Chronic Kidney Disease affects up to 1 billion people worldwide. With complications including reduced life expectancy, cardiovascular disease and dialysis... the effective detection and management of this condition has the potential to improve the lives of millions across the globe.

In this video @GoggleDocs discuss the latest Guidance from the UK Kidney Association (UKKA), which collates the latest scientific evidence for the use of SGLT2 inhibitors in Chronic Kidney Disease (CKD). This guidance was published in 2023 by a multidisciplinary team for the benefit of people living with CKD, and their healthcare professionals. It remains one of the most userfriendly and comprehensive guidelines in the field of Chronic Kidney Disease.

Follow us for more discussion on X: @GoggleDocs

TIMESTAMPS:
00:00:00 Introduction and Background
00:00:45 Why this guideline now?
00:02:20 The CKD landscape
00:04:16 What is the new guidance?
00:06:40 SGLT2i in Type 1 Diabetes
00:08:30 Frailty, CKD and SGLT2i
00:10:16 Final Thoughts

REFERENCES:
https://guidelines.ukkidney.org/
https://www.nice.org.uk/guidance/ng203
https://www.nice.org.uk/guidance/ng28
https://www.nice.org.uk/guidance/ng17
https://www.nice.org.uk/guidance/ta775
https://www.nice.org.uk/guidance/ta942
https://steno.shinyapps.io/T1RiskEngine

CREDITS:
Images: Flaticon.com Kerismaker, Parzival' 1997, Iconixar
Music: Sound Mind by Matt Large, composed by Mattias Hedbom